Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvat...

Descripción completa

Detalles Bibliográficos
Autores principales: Finn, Richard S., Ikeda, Masafumi, Zhu, Andrew X., Sung, Max W., Baron, Ari D., Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E., Saito, Kenichi, Siegel, Abby B., Dubrovsky, Leonid, Mody, Kalgi, Llovet, Josep M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479760/
https://www.ncbi.nlm.nih.gov/pubmed/32716739
http://dx.doi.org/10.1200/JCO.20.00808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479760/
https://www.ncbi.nlm.nih.gov/pubmed/32716739
http://dx.doi.org/10.1200/JCO.20.00808

Ejemplares similares